Often, during routine examinations, people are diagnosed with high cholesterol. Not everyone thinks that if its amount exceeds the norm, then this is a direct threat to cardiovascular disorders. Doctors prescribe a special diet and a set of physical activities, but such measures do not always lead to good results. Then Atorvastatin comes to the rescue. Practice has proven that the medicine produces an excellent effect in combination with therapeutic nutrition.
What does Atorvastatin help with?
Atorvastatin is a medicine that lowers blood cholesterol levels. The drug is often used for both primary and secondary prevention of cardiovascular complications. Atoris is exactly such a drug. The main active ingredient is atorvastatin. Like other statins, it suppresses the effect of an enzyme involved in the initial stage of cholesterol formation. Bad cholesterol forms atherosclerotic plaques on the walls of blood vessels, obstructing blood flow. The medicine stops cholesterol synthesis. Plaques do not grow, and atherosclerosis does not progress.
Taking this drug reduces the risk of a heart attack and prevents the development of angina pectoris. It is prescribed to patients with acute coronary syndrome. In people with ischemic stroke, Atorvastatin slightly reduces the risk of recurrence of cardiovascular changes.
Reviews
Nadezhda: I was prescribed Rosuvastatin when my cholesterol levels, to put it mildly, went through the roof. The drug is inexpensive and quite effective. After the course of treatment, cholesterol levels decreased by 2.5 units and almost returned to normal.
Veronica: My mother has atherosclerosis, she constantly drinks various medications and herbs for high cholesterol. Atorvastatin was recommended to us at a pharmacy when the medicine prescribed by the doctor was not on sale. The active ingredient in both drugs is the same, and the effect is the same, but only Atorvastatin costs three times less. We decided that we would be treated with this medicine.
Galina: Until I was 40, I thought that proper nutrition was a fashionable feature. Our parents ate everything and there were no problems. During the medical examination it turned out that I have high cholesterol. They prescribed a diet and the drug Simvastatin. I took the full course, my cholesterol dropped, but the doctor said that I couldn’t quit the diet. I have been following a healthy diet for 2 years now and periodically taking Simvastatin. The problem with cholesterol is not a concern.
Side effects
The unpleasant effects that arise from taking statins are ambiguous. In a study of healthy people taking atorvastatin, no side effects occurred. They manifest themselves in citizens at risk. Negative phenomena may be associated with the development of the disease and with the simultaneous use of other medications. The most common manifestations are:
- nausea;
- bronchitis;
- arthritis;
- infection of the genitourinary system.
Rarely, taking statins can provoke:
- diabetes;
- muscle pain;
- liver damage.
From the nervous system you can observe:
- headache;
- increased fatigue;
- dizziness;
- redness of the eyes;
- noise in ears;
- amnesia and other undesirable effects.
And:
- increased blood pressure;
- arrhythmia;
- angina pectoris;
- rhinitis;
- sinusitis;
- diarrhea;
- constipation;
- nausea;
- vomiting;
- manifestation of infections.
The problems end after stopping the drug.
Contraindications
Atorvastatin should not be taken:
- people who have severe liver diseases - chronic hepatitis, liver failure, cirrhosis;
- women of reproductive age;
- children under 18 years of age.
The therapeutic effect after taking the medicine is not immediately noticeable. This drug prevents the formation of atherosclerotic formations, but does not resolve them. The body itself copes with the gradual removal of plaques. How quickly the process moves depends on the individual. Some will need more time, some less.
Do not stop taking the medication without consulting a doctor.
Combining alcohol and statin drugs
Biotransformation of lipid-lowering drugs occurs in the liver, while the drugs undergo presystemic elimination (first-pass effect) - entering from the intestine directly into the liver and only then into the systemic bloodstream.
The liver is designed in such a way that when drinking alcoholic beverages, all functions are inhibited, except one - the processing and neutralization of ethanol. The body tries to neutralize the effects of alcohol as quickly as possible and rid the body of alcohol toxins.
When statins and alcohol simultaneously enter the body, hepatocytes (liver cells) completely switch to the rapid processing of ethanol and its breakdown products. Biotransformation of statins becomes an additional burden.
Unprocessed pharmacological substances are concentrated in the liver, and the therapeutic effect is lost, but their aggressive effect is affected. Because of this, when there is a correlation between alcoholic beverages and hypocholesterol medications, side effects from the medication occur. Alcohol intoxication, in turn, increases the symptoms of undesirable effects.
In chronic alcoholism, some hepatocytes are inoperative. Simultaneous processing of ethanol and statins by the liver becomes impossible. Considering that a contraindication to statin treatment is exacerbation of chronic liver diseases, there is a risk of developing liver failure.
Alcohol increases blood pressure and heart rate, which is especially dangerous when taking lipid-lowering drugs.
Ethanol increases the load on the kidney apparatus. When combining statins with alcohol, the active substance of the medication and the breakdown products of alcohol are retained in the body and poison the kidneys.
Alcoholic drinks irritate the mucous membrane of the gastrointestinal tract, statin drugs, like chemicals, enhance the ulcerogenic (corrosive) effect, which provokes the development of erosive and ulcerative defects.
Who is Atorvastatin useful for?
Statins are indicated for people at risk. Healthy patients are not recommended to take them as prophylaxis. The issue has not been fully studied, and there are no effective clinical trial data. The drug is prescribed when diet, exercise, or other weight loss measures have not helped.
The main diseases for which atorvastatin is prescribed are:
- combined hyperlipidemia;
- primary or hereditary hypercholesterolemia;
- familial endogenous hypertriglyceridemia.
But the main purpose is cardiac ischemia (CHD).
In pregnant women, Atorvastatin crosses the placenta and reaches high concentrations in the fetal liver. It was not tested in humans, but in rats it was established that the survival rate of offspring was reduced. Among the surviving rodents, a decrease in body weight and developmental delays were noted.
If Atorvastatin is used simultaneously with antibiotics and clarithromycin, myopathy may progress, and the concentration of the substance in the blood plasma can increase by 40%.
Antacids - medicines used to treat the stomach - reduce the concentration of atorvastatin in the blood by 35%.
Registration number:
LP-000142
Tradename:
Atorvastatin
International nonproprietary name:
atorvastatin
Dosage form:
film-coated tablets
Included in the list: VED
Dispensed: with doctor's prescription
Composition DESCRIPTION
1 film-coated tablet contains:
active substance:
atorvastatin calcium trihydrate - 0.01079 g or 0.02158 g in terms of atorvastatin - 0.01000 g or 0.02000 g;
Excipients:
lactose monohydrate - 0.09514 g or 0.1233 g, microcrystalline cellulose - 0.01015 g or 0.02080 g, calcium carbonate - 0.02175 g or 0.03120 g, croscarmellose sodium (primellose) - 0.00072 g or 0.00104 g, magnesium stearate - 0.00145 g or 0.00208 g;
shell composition:
for a dosage of 10 mg: Opadry II White - 0.0049 g (polyvinyl alcohol, titanium dioxide, talc, macrogol (polyethylene glycol)), silicone emulsion - 0.0001 g;
for a dosage of 20 mg: Opadry II Blue - 0.00785 g (polyvinyl alcohol, titanium dioxide, talc, macrogol (polyethylene glycol), aluminum varnish based on indigo carmine), silicone emulsion - 0.00015 g.
DESCRIPTION
Film-coated tablets are white (for a dosage of 10 mg) or blue (for a dosage of 20 mg), round, biconvex. Slight surface roughness is acceptable. The color of the tablets on the cross section is from white to white with a yellow tint.
PHARMACOTHERAPEUTIC GROUP
lipid-lowering agent, HMG-CoA reductase inhibitor.
ATC code
: [C10AA05]
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics.
A lipid-lowering drug from the group of statins. A selective competitive inhibitor of HMG-CoA reductase, an enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A into mevalonic acid, which is a precursor of sterols, including cholesterol. Triglycerides (TG) and cholesterol in the liver are incorporated into very low-density lipoproteins (VLDL), enter the blood plasma and are transported to peripheral tissues. Low-density lipoproteins (LDL) are formed from VLDL through interaction with LDL receptors. Atorvastatin reduces the concentrations of cholesterol and lipoproteins in the blood plasma by inhibiting HMG-CoA reductase, cholesterol synthesis in the liver and an increase in the number of “liver” LDL receptors on the cell surface, which leads to increased uptake and catabolism of LDL. Reduces the formation of LDL, causes a pronounced and persistent increase in the activity of LDL receptors. Reduces the concentration of LDL in patients with homozygous familial hypercholesterolemia, which usually does not respond to treatment with lipid-lowering drugs. Reduces the concentration of total cholesterol by 30-46%, LDL - by 41-61%, apolipoprotein B - by 34-50% and TG - by 14-33%; causes an increase in the concentration of HDL cholesterol (high density lipoprotein) and apolipoprotein A. Dose-dependently reduces the concentration of LDL in patients with homozygous hereditary hypercholesterolemia, resistant to therapy with other lipid-lowering drugs.
Pharmacokinetics.
Absorption is high. The maximum concentration (Cmax) in the blood plasma is achieved after 1-2 hours, Cmax in women is 20% higher, the area under the concentration-time curve (AUC) is 10% lower; in case of liver failure in patients with alcoholic cirrhosis of the liver (Child-Pugh B scale), Cmax and AUC increase by 16 and 11 times, respectively.
Food slightly reduces the rate and duration of drug absorption (by 25% and 9%, respectively), but the reduction in LDL cholesterol is similar to that when using Atorvastatin without food. The concentration of atorvastatin when used in the evening is lower than in the morning (by approximately 30%). A linear relationship was revealed between the degree of absorption and the dose of the drug.
Bioavailability - 12%, systemic bioavailability of inhibitory activity against HMG-CoA reductase - 30%. Low systemic bioavailability is due to first-pass metabolism in the mucous membrane of the gastrointestinal tract and during the “first pass” through the liver.
The average volume of distribution is 381 l, binding to plasma proteins is 98%. Metabolized primarily in the liver under the influence of the CYP3A4 isoenzyme with the formation of pharmacologically active metabolites (ortho- and parahydroxylated derivatives, beta-oxidation products). In vitro, ortho- and parahydroxylated metabolites have an inhibitory effect on HMG-CoA reductase comparable to that of atorvastatin. The inhibitory effect of the drug on HMG-CoA reductase is approximately 70% determined by the activity of circulating metabolites.
Excreted in bile after hepatic and/or extrahepatic metabolism (not subject to pronounced enterohepatic recirculation).
The half-life is 14 hours. Inhibitory activity against HMG-CoA reductase lasts for about 20-30 hours due to the presence of active metabolites. Less than 2% of the dose taken orally is determined in the urine. Not excreted during hemodialysis. INDICATIONS FOR USE
Atorvastatin is used:
- in combination with diet to reduce elevated concentrations of total cholesterol, cholesterol/LDL, apolipoprotein B and triglycerides and increase concentrations of HDL cholesterol in patients with primary hypercholesterolemia, heterozygous familial and non-familial hypercholesterolemia and combined (mixed) hyperlipidemia (Fredrickson types IIa and IIb) ;
- in combination with a diet for the treatment of patients with elevated serum concentrations of triglycerides (Fredrickson type IV) and patients with dysbetalipoproteinemia (Fredrickson type III) in whom diet therapy does not provide an adequate effect;
- to reduce the concentrations of total cholesterol and cholesterol/LDL in patients with homozygous familial hypercholesterolemia, when diet therapy and other non-pharmacological treatments are not effective enough. CONTRAINDICATIONS
- increased sensitivity to the components of the drug;
- active liver disease or increased activity of liver enzymes of unknown origin (more than 3 times compared to the upper limit of normal);
-liver failure (severity on the Child-Pugh scale A and B)
-pregnancy;
- lactation period;
-women of reproductive age who do not use adequate methods of contraception;
- age under 18 years (efficacy and safety have not been established). CAREFULLY
Alcohol abuse, history of liver disease, severe electrolyte imbalance, endocrine and metabolic disorders, arterial hypotension, severe acute infections (sepsis), uncontrolled epilepsy, major surgery, trauma, skeletal muscle diseases.
USE IN PREGNANCY AND LACTATION
Atorvastatin is contraindicated for use during pregnancy and lactation (breastfeeding).
It is not known whether atorvastatin is excreted in breast milk. Considering the possibility of adverse events in infants, if it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be decided.
Women of reproductive age should use adequate contraception during treatment. Atorvastatin can be used in women of reproductive age only if the likelihood of pregnancy is very low and the patient is informed about the possible risk of treatment to the fetus. METHOD OF APPLICATION AND DOSES
Before prescribing Atorvastatin, the patient should be recommended a standard lipid-lowering diet, which he should continue to follow throughout the entire period of therapy.
The initial dose is on average 10 mg 1 time / day. The dose varies from 10 to 80 mg 1 time/day.
The drug can be taken at any time of the day with food or regardless of meal time. The dose is selected taking into account the initial concentrations of cholesterol/LDL, the goal of therapy and individual effect. At the beginning of treatment and/or while increasing the dose of Atorvastatin, it is necessary to monitor the concentration of lipids in the blood plasma every 2-4 weeks and adjust the dose accordingly.
Primary hypercholesterolemia and mixed hyperlipidemia, as well as Fredrickson types III and IV.
In most cases, a dose of 10 mg of Atorvastatin once a day is sufficient. A significant therapeutic effect is observed after 2 weeks, as a rule, and the maximum therapeutic effect is usually observed after 4 weeks. With long-term treatment, this effect persists.
Homozygous familial hypercholesterolemia.
Used in a dose of 80 mg (4 tablets of 20 mg) 1 time per day.
The use of the drug in patients with renal failure and kidney disease does not affect the level of Atorvastatin in the blood plasma or the degree of reduction in cholesterol/LDL during its use, so no change in the dose of the drug is required.
In case of liver failure, the dose must be reduced (see section “With caution” and “Special instructions”).
When using the drug in elderly patients, there were no differences in safety, effectiveness, or achievement of lipid-lowering therapy goals compared to the general population. SIDE EFFECT
From the nervous system:
more often 2% - insomnia, dizziness; less often 2% - headache, asthenia, malaise, drowsiness, nightmares, paresthesia, peripheral neuropathy, amnesia, emotional lability, ataxia, facial paralysis, hyperkinesis, migraine, depression, hypoesthesia, loss of consciousness.
From the senses:
less often 2% - amblyopia, ringing in the ears, dry conjunctiva, impaired accommodation, hemorrhage in the retina, deafness, glaucoma, parosmia, loss of taste, perversion of taste.
From the cardiovascular system:
more often 2% - chest pain; less than 2% - palpitations, symptoms of vasodilation, orthostatic hypotension, increased blood pressure, phlebitis, arrhythmia, angina pectoris.
From the hematopoietic system:
less often 2% - anemia, lymphadenopathy, thrombocytopenia.
From the respiratory system:
more often 2% - bronchitis, rhinitis; less often 2% - pneumonia, dyspnea, exacerbation of bronchial asthma, nosebleeds.
From the digestive system:
more often 2% - nausea; less than 2% - heartburn, constipation or diarrhea, flatulence, gastralgia, abdominal pain, decreased or increased appetite, dry oral mucosa, belching, dysphagia, vomiting, stomatitis, esophagitis, glossitis, erosive and ulcerative lesions of the oral mucosa, gastroenteritis, hepatitis, biliary colic, cheilitis, duodenal ulcer, pancreatitis, cholestatic jaundice, liver dysfunction, rectal bleeding, melena, bleeding gums, tenesmus.
From the musculoskeletal system:
more often 2% - arthritis; less than 2% - leg muscle cramps, bursitis, tenosynovitis, myositis, myopathy, arthralgia, myalgia, rhabdomyolysis, torticollis, muscle hypertonicity, joint contractures.
From the genitourinary system:
more often 2% - urogenital infections, peripheral edema; less than 2% - dysuria (including pollakiuria, nocturia, urinary incontinence or urinary retention, urinary urgency), nephritis, hematuria, vaginal bleeding, nephrourolithiasis, metrorrhagia, epididymitis, decreased libido, impotence, ejaculation disorder, secondary renal failure.
From the skin:
more often 2% - alopecia, xeroderma, increased sweating, eczema, seborrhea, ecchymosis, petechiae.
Allergic reactions:
less than 2% - itching, rash, contact dermatitis, rarely - urticaria, angioedema, facial swelling, photosensitivity, anaphylaxis, exudative erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome).
Laboratory indicators:
less than 2% - hyperglycemia, hypoglycemia, increased serum CPK activity, albuminuria.
Other:
less often 2% - weight gain, gynecomastia, mastodynia, exacerbation of gout.
OVERDOSE
Treatment: there is no specific antidote, symptomatic therapy is carried out.
Hemodialysis is ineffective. INTERACTIONS WITH OTHER MEDICINES
The risk of myopathy during treatment with other drugs of this class increases with simultaneous use of cyclosporine, fibrates, erythromycin, clarithromycin, immunosuppressive, azole antifungal drugs, and nicotinic acid in lipid-lowering doses.
When simultaneous oral administration of Atorvastatin and a suspension containing magnesium and aluminum hydroxide, the concentrations of Atorvastatin in the blood plasma decreased by approximately 35%, but the degree of reduction in the concentration of cholesterol/LDL did not change.
With simultaneous use, Atorvastatin does not affect the pharmacokinetics of phenazone (antipyrine), so interaction with other drugs metabolized by the same cytochrome CYP 3A4 isoenzymes is not expected.
With simultaneous use of colestipol, the concentration of atorvastatin in the blood plasma decreased by approximately 25%. However, the lipid-lowering effect of the combination of Atorvastatin and colestipol was superior to that of each drug alone.
With repeated use of digoxin and atorvastatin at a dose of 10 mg, the equilibrium concentrations of digoxin in the blood plasma did not change. However, when using digoxin in combination with Atorvastatin at a dose of 80 mg/day. Digoxin concentrations increased by approximately 20%. Patients receiving digoxin in combination with Atorvastatin should be monitored.
With the simultaneous use of Atorvastatin and erythromycin (500 mg 4 times / day) or clarithromycin (500 mg 2 times / day), which inhibit the CYP 3A4 isoenzyme, an increase in the concentration of Atorvastatin in the blood plasma was observed.
With simultaneous use of Atorvastatin (10 mg 1 time / day) and azithromycin (500 mg 1 time / day), the concentration of Atorvastatin in the blood plasma did not change.
Atorvastatin did not have a clinically significant effect on the plasma concentration of terfenadine, which is metabolized mainly by the CYP 3A4 isoenzyme; in this regard, it seems unlikely that Atorvastatin can significantly affect the pharmacokinetic parameters of other substrates of the CYP 3A4 isoenzyme.
When Atorvastatin was coadministered with an oral contraceptive containing norethisterone and ethinyl estradiol, significant increases in the AUC of norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively, were observed. This effect should be taken into account when choosing an oral contraceptive for a woman receiving Atorvastatin.
Concomitant use with drugs that reduce the concentration of endogenous steroid hormones (including cimetidine, ketoconazole, spironolactone) increases the risk of a decrease in endogenous steroid hormones (caution should be exercised).
When studying the interaction of Atorvastatin with warfarin and cimetidine, no signs of clinically significant interaction were found.
With simultaneous use of Atorvastatin 80 mg and amlodipine 10 mg, the pharmacokinetics of Atorvastatin at steady state did not change.
There were no clinically significant adverse interactions between Atorvastatin and antihypertensive drugs.
The simultaneous use of Atorvastatin with protease inhibitors, known as inhibitors of the CYP 3A4 isoenzyme, was accompanied by an increase in the concentration of Atorvastatin in the blood plasma.
No pharmaceutical incompatibilities are known. SPECIAL INSTRUCTIONS
Before starting Atorvastatin therapy, the patient must be prescribed a standard cholesterol-lowering diet, which he must follow during the entire treatment period.
The use of HMG-CoA reductase inhibitors to reduce the concentration of lipids in the blood can lead to changes in biochemical parameters reflecting liver function. Liver function should be monitored before starting therapy, 6 weeks, 12 weeks after starting Atorvastatin and after each dose increase, and periodically, for example, every 6 months. An increase in the activity of liver enzymes in the blood serum may be observed during therapy with Atorvastatin. Patients who experience increased enzyme activity should be monitored until enzyme activity returns to normal. If alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values are more than 3 times the upper acceptable limit, it is recommended to reduce the dose of Atorvastatin or discontinue treatment.
Atorvastatin should be used with caution in patients who abuse alcohol and/or have liver disease. Active liver disease or a persistent increase in the activity of liver transaminases of unknown origin are contraindications to the use of Atorvastatin.
Treatment with Atorvastatin may cause myopathy. The diagnosis of myopathy (muscle pain and weakness in combination with an increase in CPK activity by more than 10 times the upper limit of normal) should be in patients with widespread myalgias, muscle soreness or weakness and/or a marked increase in CPK activity. Patients should be warned that they should immediately tell their doctor if they experience unexplained muscle pain or weakness if they are accompanied by malaise or fever. Atorvastatin therapy should be discontinued in the event of a marked increase in CPK activity or in the presence of confirmed or suspected myopathy. The risk of myopathy during treatment with other drugs of this class increases with simultaneous use of cyclosporine, fibrates, erythromycin, clarithromycin, immunosuppressives, azole antifungals, and nicotinic acid in lipid-lowering doses. Many of these drugs inhibit CYP3A4-mediated metabolism and/or drug transport. Atorvastatin is biotransformed under the action of the CYP 3A4 isoenzyme. When using Atorvastatin concomitantly with fibrates, erythromycin, immunosuppressive agents, azole antifungals or nicotinic acid in lipid-lowering doses, the expected benefits and risks of treatment should be carefully weighed and patients should be regularly monitored to detect muscle pain or weakness, especially during the first months of treatment and during periods of increasing the dose of any drug. In such situations, periodic determination of CPK activity can be recommended, although such monitoring does not prevent the development of severe myopathy.
When using Atorvastatin, as well as other drugs of this class, cases of rhabdomyolysis with acute renal failure caused by myoglobinuria have been described. Atorvastatin therapy should be temporarily discontinued or discontinued if signs of possible myopathy occur or if there is a risk factor for the development of renal failure secondary to rhabdomyolysis (eg, severe acute infection, hypotension, major surgical procedures, trauma, severe metabolic, endocrine and electrolyte disturbances, and uncontrolled seizures ).
Before starting therapy with Atorvastatin, an attempt should be made to control hypercholesterolemia through adequate diet therapy, increased physical activity, weight loss in obese patients, and treatment of other conditions.
There are reports of the development of atonic fasciitis during the use of Atorvastatin, however, a connection with taking the drug is possible, but has not yet been proven, the etiology is unknown.
Impact on the ability to drive vehicles and operate machinery
No adverse effects of Atorvastatin on the ability to drive vehicles or operate machinery have been reported. RELEASE FORM
Film-coated tablets, 10 mg and 20 mg.
7 or 10 tablets per blister pack.
1, 2, 3 or 4 blister packs along with instructions for use in a cardboard pack. STORAGE CONDITIONS
In a dry place, protected from light, at a temperature not exceeding 25 ° C.
Keep out of the reach of children. BEST BEFORE DATE
3 years. Do not use after the expiration date stated on the package. CONDITIONS OF VACATION FROM PHARMACIES
Dispensed by prescription.
MANUFACTURER
CJSC "Biocom", Russia, 355016, Stavropol, Chapaevsky proezd, 54. Tel., 36-53-54Fax
Send consumer complaints to the manufacturer.
Analogs
All generics of atorvastatin are available in the form of film-coated tablets.
The price of the original drug varies from 120 to 580 rubles.
- Atorvastatin Teva has moved a little higher in terms of monitoring, and the cost is lower than the original drug.
- The drug Atoris deserves more attention, but its price is from 300 to 1000 rubles.
- Tarvocard, according to experts, is more effective than Atoris, but its cost reaches 1,400 rubles.
- The undisputed leader among doctors is Liprimar. A reflection of his primacy can be seen in the price tag: from 600 to 2500 rubles.
Expert advice
Atorvastatin is produced by many pharmaceutical companies, but not all of them show good results. Cheap analogues often have an annoying property - frequent side effects. It is difficult to understand the production technology of companies that are not drug developers. They sometimes carefully hide secrets.
Doctors recommend choosing only those medications that have positive results of therapeutic equivalence analysis. Atoris, for example, a studied analogue, is popular with doctors. “Faceless” tablets priced from 100 to 200 rubles should raise concerns: side effects can strike with enormous force, and the desired therapeutic result will never be achieved. When choosing a drug, it is better to trust your doctor. Most of them still want to cure the patient, and only they can know which medicine is suitable in a particular case.
conclusions
Atorvastatin is a synthetic drug from the Statin group used to treat dyslipidemia, hypercholesterolemia and prevent complications in patients with atherosclerosis and cardiovascular pathology. Before prescribing the Atorvastatin regimen, a general examination and blood sampling to assess cholesterol levels, LDL and HDL fractions, and triglycerides are indicated. Taking into account the risk of adverse reactions, the calculation of the dosage and duration of taking the medication is carried out by a general practitioner or cardiologist.
